Agenus Provides Corporate Update and First Quarter 2023 Financial Results

At a late-breaking presentation at ASCO-GI, botensilimab/balstilimab combination demonstrated a 63% 12-month overall survival rate in metastatic colorectal cancer patients who have failed a median... | May 9, 2023

Related Keywords

United States ,New York ,Barcelona ,Comunidad Autonoma De Cataluna ,Spain ,Chicago ,Illinois ,American ,Garo Armen ,Agenus Inc ,Society Of Gynecologic Oncology ,Twitter ,Nasdaq ,American Society Of Clinical Oncology ,World Congress On Gastrointestinal Cancer ,Exchange Commission ,Chief Executive Officer ,American Society ,Clinical Oncology ,Gastrointestinal Cancers Symposium ,Gynecologic Oncology ,Fast Track Designation ,Gastrointestinal Cancer ,Combination With ,First Line Treatment ,Patients With ,Metastatic Squamous Cell Carcinoma ,Combination Therapy ,With Advanced Solid Tumors ,Risk Factors ,Quarterly Report ,Annual Report ,Agenus Inc Stock Exchange ,News ,Information ,Press Release ,It ,Presentation ,Combination ,Remonstrated ,Verall ,Survival ,Gate ,N ,Metastatic ,Olorectal ,Dancer ,Patients ,Who ,Wave ,Ailed Agen Us00847g7051 ,